G
Geertjan van Tienhoven
Researcher at University of Amsterdam
Publications - 139
Citations - 9773
Geertjan van Tienhoven is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Radiation therapy & Medicine. The author has an hindex of 35, co-authored 113 publications receiving 7715 citations. Previous affiliations of Geertjan van Tienhoven include University of Maryland, Baltimore County.
Papers
More filters
Journal ArticleDOI
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
M. Donker,Geertjan van Tienhoven,Marieke E. Straver,P. Meijnen,Cornelis J.H. van de Velde,Robert E. Mansel,Luigi Cataliotti,A. Helen Westenberg,Jean H. G. Klinkenbijl,Lorenzo Orzalesi,Willem H. Bouma,Huub van der Mijle,Grard A. P. Nieuwenhuijzen,Sanne C. Veltkamp,Leen Slaets,Nicole Duez,Peter W. de Graaf,Thijs van Dalen,A. Marinelli,Herman Rijna,Marko Snoj,Nigel J Bundred,Jos W. S. Merkus,Yazid Belkacemi,Patrick Petignat,Dominic A.X. Schinagl,Corneel Coens,Carlo Messina,Jan Bogaerts,Emiel J. Th. Rutgers +29 more
TL;DR: The AMAROS trial as discussed by the authors evaluated axillary lymph node dissection and axillary radiotherapy for T1-2 primary breast cancer and no palpable lymphadenopathy patients with positive sentinel nodes.
Journal ArticleDOI
Duration of androgen suppression in the treatment of prostate cancer.
Michel Bolla,Theodorus M. de Reijke,Geertjan van Tienhoven,Alphonsus C.M. van den Bergh,Jorg R. Oddens,Philip Poortmans,Eliahu Gez,Paul Kil,Atif Akdas,Guy Soete,Oleg B. Kariakine,Elsbietha M. van der Steen-Banasik,Elena Musat,Marianne Pierart,Murielle Mauer,Laurence Collette +15 more
TL;DR: The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapyplus 3 years of androgens suppression in the treatment of locally advanced prostate cancer.
Journal ArticleDOI
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
Michel Bolla,Geertjan van Tienhoven,Padraig Warde,Jean Bernard Dubois,René-Olivier Mirimanoff,Guy Storme,Jacques Bernier,Abraham Kuten,Cora N. Sternberg,Ignace Billiet,José Lopez Torecilla,Raphael Pfeffer,Carmel Lino Cutajar,Theodore H. van der Kwast,Laurence Collette +14 more
TL;DR: In patients with prostate cancer with high metastatic risk, immediate androgen suppression with an LHRH agonist given during and for 3 years after external irradiation improves 10-year disease-free and overall survival without increasing late cardiovascular toxicity.
Journal ArticleDOI
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
Michel Bolla,Hein Van Poppel,Bertrand Tombal,K. Vekemans,Luigi F. Da Pozzo,Theo M. de Reijke,Antony Verbaeys,Jean-François Bosset,Roland Van Velthoven,Marc Colombel,Cees van de Beek,Paul C.M.S. Verhagen,Alphonsus C.M. van den Bergh,Cora N. Sternberg,Thomas C. Gasser,Geertjan van Tienhoven,Pierre Scalliet,Karin Haustermans,Laurence Collette +18 more
TL;DR: Results at median follow-up of 10·6 years show that conventional postoperative irradiation significantly improves biochemical progression-free survival and local control compared with a wait-and-see policy, supporting results at 5 year follow- up; however, improvements in clinical progression- free survival were not maintained.
Journal ArticleDOI
The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study
Elsbeth Steenland,J.W.H. Leer,Hans C. van Houwelingen,Wendy J. Post,Wilbert B. van den Hout,Job Kievit,Hanneke C. J. M. de Haes,Hendrik Martijn,Bing Oei,Ernest Vonk,Elzbieta van der Steen-Banasik,Ruud Wiggenraad,J. Hoogenhout,C.C. Wárlám-Rodenhuis,Geertjan van Tienhoven,Rinus Wanders,J. Pomp,M. van Reijn,Thijs van Mierlo,Ewald H. J. M. Rutten +19 more
TL;DR: The global analysis of the Dutch study indicates the equality of a single fraction as compared to a 6 fraction treatment in patients with painful bone metastases provided that 4 times more retreatments are accepted in the single dose group.